# Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

> **NCT07068191** · NA · RECRUITING · sponsor: **Phenomen Pharma** · enrollment: 90 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Hepatomegaly
- Nonalcoholic Fatty Liver (NAFL)
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Fatty Liver
- Fatty Liver, Alcoholic
- Fatty Liver, Nonalcoholic
- Fatty Liver Disease

## Interventions

- **COMBINATION_PRODUCT:** Dietary supplement "Gepaktiv"
- **DRUG:** UDCA (Ursodeoxycholic acid)
- **DRUG:** Ademetionine

## Key facts

- **NCT ID:** NCT07068191
- **Lead sponsor:** Phenomen Pharma
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-19
- **Primary completion:** 2025-07
- **Final completion:** 2025-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07068191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07068191, "Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07068191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*